114 related articles for article (PubMed ID: 22613430)
1. Frequent SLIT2 promoter methylation in the serum of patients with ovarian cancer.
Dong R; Yu J; Pu H; Zhang Z; Xu X
J Int Med Res; 2012; 40(2):681-6. PubMed ID: 22613430
[TBL] [Abstract][Full Text] [Related]
2. Detection of Slit2 promoter hypermethylation in tissue and serum samples from breast cancer patients.
Kim GE; Lee KH; Choi YD; Lee JS; Lee JH; Nam JH; Choi C; Park MH; Yoon JH
Virchows Arch; 2011 Oct; 459(4):383-90. PubMed ID: 21894562
[TBL] [Abstract][Full Text] [Related]
3. SLIT2 is epigenetically silenced in ovarian cancers and suppresses growth when activated.
Qiu H; Zhu J; Yu J; Pu H; Dong R
Asian Pac J Cancer Prev; 2011; 12(3):791-5. PubMed ID: 21627385
[TBL] [Abstract][Full Text] [Related]
4. A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA.
Zhang Q; Hu G; Yang Q; Dong R; Xie X; Ma D; Shen K; Kong B
Gynecol Oncol; 2013 Jul; 130(1):132-9. PubMed ID: 23623832
[TBL] [Abstract][Full Text] [Related]
5. Promoter hypermethylation of SLIT2 is a risk factor and potential diagnostic biomarker for nasopharyngeal carcinoma.
Li J; Zhou C; Wang G; Wang S; Ni S; Ye M; Zhang J
Gene; 2018 Feb; 644():74-79. PubMed ID: 29107007
[TBL] [Abstract][Full Text] [Related]
6. Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients.
Sharma G; Mirza S; Prasad CP; Srivastava A; Gupta SD; Ralhan R
Life Sci; 2007 Apr; 80(20):1873-81. PubMed ID: 17383681
[TBL] [Abstract][Full Text] [Related]
7. SLIT2 promoter methylation analysis in neuroblastoma, Wilms' tumour and renal cell carcinoma.
Astuti D; Da Silva NF; Dallol A; Gentle D; Martinsson T; Kogner P; Grundy R; Kishida T; Yao M; Latif F; Maher ER
Br J Cancer; 2004 Jan; 90(2):515-21. PubMed ID: 14735202
[TBL] [Abstract][Full Text] [Related]
8. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients.
Ibanez de Caceres I; Battagli C; Esteller M; Herman JG; Dulaimi E; Edelson MI; Bergman C; Ehya H; Eisenberg BL; Cairns P
Cancer Res; 2004 Sep; 64(18):6476-81. PubMed ID: 15374957
[TBL] [Abstract][Full Text] [Related]
9. Silencing of tumor suppressor genes RASSF1A, SLIT2, and WIF1 by promoter hypermethylation in hereditary breast cancer.
Alvarez C; Tapia T; Cornejo V; Fernandez W; Muñoz A; Camus M; Alvarez M; Devoto L; Carvallo P
Mol Carcinog; 2013 Jun; 52(6):475-87. PubMed ID: 22315090
[TBL] [Abstract][Full Text] [Related]
10. Frequent epigenetic inactivation of the SLIT2 gene in gliomas.
Dallol A; Krex D; Hesson L; Eng C; Maher ER; Latif F
Oncogene; 2003 Jul; 22(29):4611-6. PubMed ID: 12881718
[TBL] [Abstract][Full Text] [Related]
11. SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers.
Dallol A; Da Silva NF; Viacava P; Minna JD; Bieche I; Maher ER; Latif F
Cancer Res; 2002 Oct; 62(20):5874-80. PubMed ID: 12384551
[TBL] [Abstract][Full Text] [Related]
12. Detection of aberrant methylation of HOXA9 and HIC1 through multiplex MethyLight assay in serum DNA for the early detection of epithelial ovarian cancer.
Singh A; Gupta S; Badarukhiya JA; Sachan M
Int J Cancer; 2020 Sep; 147(6):1740-1752. PubMed ID: 32191343
[TBL] [Abstract][Full Text] [Related]
13. BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).
Ruscito I; Dimitrova D; Vasconcelos I; Gellhaus K; Schwachula T; Bellati F; Zeillinger R; Benedetti-Panici P; Vergote I; Mahner S; Cacsire-Tong D; Concin N; Darb-Esfahani S; Lambrechts S; Sehouli J; Olek S; Braicu EI
Eur J Cancer; 2014 Aug; 50(12):2090-8. PubMed ID: 24889916
[TBL] [Abstract][Full Text] [Related]
14. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer.
Hoque MO; Begum S; Topaloglu O; Jeronimo C; Mambo E; Westra WH; Califano JA; Sidransky D
Cancer Res; 2004 Aug; 64(15):5511-7. PubMed ID: 15289362
[TBL] [Abstract][Full Text] [Related]
15. SLIT2 promoter hypermethylation predicts disease progression in chronic myeloid leukemia.
Wu DL; Wang Y; Zhang TJ; Chu MQ; Xu ZJ; Yuan Q; Ma JC; Lin J; Qian J; Zhou JD
Eur J Med Res; 2022 Nov; 27(1):259. PubMed ID: 36411451
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic inactivation of SLIT2 in human hepatocellular carcinomas.
Jin J; You H; Yu B; Deng Y; Tang N; Yao G; Shu H; Yang S; Qin W
Biochem Biophys Res Commun; 2009 Jan; 379(1):86-91. PubMed ID: 19100240
[TBL] [Abstract][Full Text] [Related]
17. Frequent epigenetic inactivation of the SLIT2 gene in chronic and acute lymphocytic leukemia.
Dunwell TL; Dickinson RE; Stankovic T; Dallol A; Weston V; Austen B; Catchpoole D; Maher ER; Latif F
Epigenetics; 2009 May; 4(4):265-9. PubMed ID: 19550140
[TBL] [Abstract][Full Text] [Related]
18. Loss of expression and promoter methylation of SLIT2 are associated with sessile serrated adenoma formation.
Beggs AD; Jones A; Shepherd N; Arnaout A; Finlayson C; Abulafi AM; Morton DG; Matthews GM; Hodgson SV; Tomlinson IP
PLoS Genet; 2013 May; 9(5):e1003488. PubMed ID: 23671423
[TBL] [Abstract][Full Text] [Related]
19. Methylation status of the gene promoter of cyclin-dependent kinase inhibitor 2A (CDKN2A) in ovarian cancer.
Abou-Zeid AA; Azzam AZ; Kamel NA
Scand J Clin Lab Invest; 2011 Nov; 71(7):542-7. PubMed ID: 21728901
[TBL] [Abstract][Full Text] [Related]
20. SLIT2 axon guidance molecule is frequently inactivated in colorectal cancer and suppresses growth of colorectal carcinoma cells.
Dallol A; Morton D; Maher ER; Latif F
Cancer Res; 2003 Mar; 63(5):1054-8. PubMed ID: 12615722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
